B cell lymphoma is a major class of spontaneous malignant disease, and its occurence is strongly correlated with increasing age, genetic background, and certain acquire immunodeficient states. In the previous grant period, we characterized the pattern of I expression and growth control in long-term Ly-1+ B cell lines (B-Ly1 cells). In particular, we noted that these cells displayed neoplastic growth properties in vitro and various degrees of tumorigenicity in vivo' despite their original derivation from normal mice. B-Ly1 cell lines thus appear to offer a new in vitro lymphomagenesis model to recover and study neoplastic B cells at early stages of malignant progression. In the rew grant period, we use this model to test the hypothesis that the initial stages of B cell lymphomagenesis represent an aberrant but potentially reversible differentiative state.
Our specific aims address these questions: What are the recipient host mechanisms which suppress tumorigenicity B-Ly1 cells? The host cell types and cytokines which suppress tumorigenicity and in vitro B-Ly1 cell growth will be defined. We will also determine whether the mechanism is cytotoxic, or it instead involves differentiation of B-Ly1 cells into a non-tumorigenic state. What subpopulation serves as the precursor for B-Ly1 cell lines? Using a quantitative in vitro outgrowth assay, we will characterize the phenotype of the in vivo precursor cell according to pattern of surface differentiatior antigens and Ig variable region and isotype expression. In addition, we will directly monitor the in vivo properties of a representative Ly-1+ B cell population expressing a characteristic VH gene family recently cloned in our laboratory. Which of these host and precursor parameters account for the elevated occurrence of lymphoma in the aged individual, and as a consequence of certain genetic or acquired traits? We will assess whether experimentally-defined mechanisms permissive for B-Ly1 neoplastic growth correlate with murine animal models exemplifying natural lymphomagenic processes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA049308-01
Application #
3193385
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-01-09
Project End
1993-12-31
Budget Start
1989-01-09
Budget End
1989-12-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Fairhurst, R M; Valles-Ayoub, Y; Neshat, M et al. (1996) A DNA repair abnormality specific for rearranged immunoglobulin variable genes in germinal center B cells. Mol Immunol 33:231-44
Goodglick, L; Felsher, D W; Neshat, M S et al. (1995) A novel octamer regulatory element in the VH11 leader exon of B-1 cells. J Immunol 154:4546-56
Goodglick, L; Zevit, N; Neshat, M S et al. (1995) Mapping the Ig superantigen-binding site of HIV-1 gp120. J Immunol 155:5151-9
Goodglick, L; Braun, J (1994) Revenge of the microbes. Superantigens of the T and B cell lineage. Am J Pathol 144:623-36
Krall, W J; Braun, J (1992) In situ lacZ retrovirus-marked lymphocytes define a B cell microenvironment in the lymph node medulla. New Biol 4:581-90
Braun, J; Felsher, D W; Goodglick, L A (1992) c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. Ann N Y Acad Sci 651:467-9
Felsher, D W; Ando, D T; Braun, J (1991) Independent rearrangement of Ig lambda genes in tissue culture-derived murine B cell lines. Int Immunol 3:711-8
Felsher, D W; Rhim, S H; Braun, J (1990) A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines. Cancer Res 50:7050-6
Felsher, D W; Denis, K A; Weiss, D et al. (1990) A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype. Cancer Res 50:7042-9